Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
1979
|
| gptkbp:ATCCode |
N02AF02
|
| gptkbp:brand |
gptkb:nalbuphine
|
| gptkbp:contraindication |
respiratory depression
hypersensitivity to nalbuphine |
| gptkbp:controlledSubstanceSchedule |
No (US)
|
| gptkbp:developedBy |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:drugClass |
gptkb:opioid
|
| gptkbp:eliminationHalfLife |
5 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:form |
injectable solution
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
opioid receptor agonist-antagonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:routeOfAdministration |
intramuscular
subcutaneous intravenous |
| gptkbp:sideEffect |
nausea
dizziness sweating respiratory depression sedation |
| gptkbp:usedFor |
pain management
|
| gptkbp:bfsParent |
gptkb:nalbuphine
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
Nubain
|